Growth through acquisition Verista recently expanded by acquiring Hawkins Point, signaling a strategy of scaling capabilities and expanding service breadth in life sciences consulting. Sales opportunities may arise from cross-selling enhanced end-to-end drug development and patient journey solutions to existing Hawkins Point clients and new prospects seeking integrated capabilities.

Mid-market focus With 51-200 employees and revenue in the 1M-10M range, Verista operates in the mid-market segment. This suggests opportunity for scalable, high-value partnerships with life sciences firms that require niche expertise in discovery to delivery, regulatory quality, and IT compliance without engaging large top-tier firms.

Domain expertise pitch The firm emphasizes deep life sciences domain expertise across the drug development lifecycle and patient journey. Sales conversations can emphasize proven industry specialists, quality and integrity in delivery, and the ability to de-risk complex programs through specialized consulting and technology-enabled solutions.

Technology stack leverage Existing tech stack includes Qlik Sense, Veeva CRM, HIPAA, Google Analytics, and data/security tools. Opportunities exist to position Verista as a trusted partner for clients needing data analytics, regulatory/compliance IT support, and modern digital transformation across clinical and commercial operations.

Leadership and growth story Historical leadership additions and recognition as a fast-growing private company, plus investor backing, provide a compelling narrative for partnerships with firms seeking agile, mission-driven collaborators. Target prospects can include biotech and pharma companies pursuing rapid development, quality assurance, and scalable commercialization support.